Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanfeng Zou has a total of 166 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Wang

    Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

    16 shared publications
  • Hong Su

    Department of Epidemiology and Biostatistics, School of Public Health Anhui Medical University Hefei Anhui China

    13 shared publications
  • Jing Cai

    Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

    13 shared publications
  • Shuang Liu

    Department of Rheumatology and Immunology The First Affiliated Hospital of Anhui Medical University Hefei Anhui China

    11 shared publications
  • Faming Pan

    Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University

    10 shared publications
  • Hongyu Sun

    Department of Epidemiology and Biostatistics, School of Public Health Anhui Medical University Hefei Anhui China

    10 shared publications

Latest Publications

  • Association of Mitochondrial DNA Genetic Variants With Depression and Anxiety in Chinese Patients With Systemic Lupus Erythematosus

    by Qiqun Zong, Yue Li, Yuxin Wang, Yaping Feng, Yingying Yu, Mingyi Zhang, Yuqin Tang, Liangyu Cui, Lin Cai, Ying Xu, et al.

    Objective: To explore the association of mitochondrial DNA (mtDNA) genetic variants, including single nucleotide variants (SNVs), insertions and deletions (InDels), and copy number variations (CNVs), with depression and anxiety in Chinese patients with systemic lupus erythematosus (SLE). Methods: A two‐stage study of 530 patients with SLE was conducted to explore the association between mtDNA genetic variants (SNVs and InDels) and depression and anxiety. A total of 499 patients with SLE were recruited to explore the association between mtDNA CNVs and depression and anxiety. Meanwhile, the patients were followed up for 12 weeks to observe the improvement of depression and anxiety. The levels of reactive oxygen species (ROS), adenosine triphosphate (ATP), interleukin‐6 (IL‐6), and interleukin‐1β (IL‐1β) were detected. Results: Two mtDNA SNVs (C16291T, A16399G) in the displacement loop (D‐loop) region were associated with depression in patients with SLE ( P BH = 0.003, P BH = 0.007). Two mtDNA SNVs (T9950C, T16140C) in the cytochrome c oxidase subunit III (COX3) gene and D‐loop region were associated with anxiety in patients with SLE ( P BH = 0.001; P BH = 0.003). Associations of mtDNA CNVs with depression and anxiety in SLE were observed in several subgroups ( P adj < 0.05). T9950C and T16140C variants were related to the improvement of anxiety in SLE ( P BH < 0.05). An inverse U‐shaped non‐linear association was observed between mtDNA CNVs and the improvement of anxiety in the body mass index (BMI) ≥ 24 subgroup of SLE ( P non‐linear = 0.038). The levels of ROS ( p = 0.040) and IL‐6 ( p = 0.039) were increased and ATP level ( p = 0.034) was decreased in the COX3 gene variation group. Conclusion: mtDNA genetic variants may be associated with depression and anxiety in Chinese patients with SLE. This study provides a new idea for improving depression and anxiety in SLE.

  • Open Access

    Association of CAB39L gene methylation in peripheral blood leukocytes with the risk, chemotherapy efficacy and prognosis of gastric cancer and construction of risk prediction model

    by Yuqi Liu, Zhan Li, Yaping Feng, Yue Li, Yuxin Wang, Hongyu Sun, Ying Xu, Xingyu Gong, Yingying Yu, Yuqin Tang, et al.

    Background: Gastric cancer (GC) is a highly prevalent malignant tumor of the digestive tract worldwide, and there is an urgent need to explore non-invasive molecular markers for supporting precise clinical diagnosis and treatment. The study was to explore the correlation between CAB39L gene methylation in peripheral blood leukocytes (PBLs) and the risk, chemotherapy efficacy, and prognosis of GC, and correspondingly construct risk prediction model. Methods: Online databases were used for bioinformatics analysis of CAB39L in GC tissues. A two-phased approach was subsequently employed: in the discovery stage (100 GC patients and 100 controls), we detected the methylation levels of all CpG sites in CAB39L to screen for potential CpG sites/regions associated with GC and response to platinum plus fluorouracil (PPF) treatment, and these findings were further validated in independent samples (250 GC patients and 250 controls). In addition, GC patients were followed up to investigate the correlation between CAB39L gene methylation and prognostic outcomes. Nomogram risk prediction models were constructed by integrating CpG sites, environmental and clinical parameters. The expression levels of CAB39L in the peripheral blood of 34 GC patients were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Finally, the gene-environment interactions were investigated. Results: Utilizing online databases, we discovered a negative association between the mRNA (messenger RNA) expression of CAB39L and the levels of DNA methylation, as well as a positive correlation with the half maximal inhibitory concentration (IC50) values of 5-fluorouracil and cisplatin in GC tissues. In two stages study, it was found that the methylation status of three sites plus two CpG islands (CAB39La2, CAB39Lb3, CAB39Lb14, CAB39L-a, CAB39L-b) were associated with the risk of GC (PBHBH0.05). Compared with the hypomethylation group of GC patients, the mRNA expression level of CAB39L in the hypermethylation group was decreased (P=0.041). Interactions between CAB39L methylation and environmental factors were observed. Conclusions: Our findings suggested that methylation of CAB39L in PBLs was associated with GC risk and chemotherapy response, and the prediction model based on CAB39L methylation site has potential value in predicting the efficacy of chemotherapy. Elevated CAB39L methylation levels of GC patients might influence gene expression. This study provides theoretical support for the diagnosis and treatment of GC patients.

  • Open Access

    Piezo1-mediated autophagy promotes immune-inflammatory responses in ankylosing spondylitis

    by Hui Zhao, Xueying Yu, Minxin Jiang, Ziqi Li, Yanyu Zhao, Yuxin Ren, Lanlan Fang, Mengmeng Wang, Xiaofeng Lu, Yubo Ma, et al.

    This study aimed to investigate the role of Piezo1 in the immune-inflammatory response during the pathogenesis of ankylosing spondylitis (AS) and its underlying mechanisms. RT-qPCR was used to evaluate the expression levels of Piezo1 and autophagy-related genes in the peripheral blood of AS patients. Correlation analyses were conducted to evaluate associations between Piezo1 expression and clinical characteristics of AS patients. Immunohistochemistry (IHC) and Western blotting were performed to determine the expression of Piezo1 and autophagy-related proteins in the synovium of AS patients. In vitro, the effects of Piezo1 and autophagy on primary monocyte-derived macrophages and fibroblast-like synoviocytes (FLS) from AS patients were investigated using Yoda1 and 3-MA interventions. Modulation of the immune-inflammatory response via the Piezo1-autophagy axis was examined through RT-qPCR, Western blotting, and ELISA. Finally, the role of Piezo1 in immune regulation was further assessed in proteoglycan-induced arthritis (PGIA) model using GsMTx4, a Piezo1 inhibitor. Piezo1 expression was markedly elevated in AS patients compared to healthy controls and showed a positive correlation with disease activity, duration, and autophagy levels. Mechanistically, increased Piezo1 expression induced M1 polarization of monocyte-macrophages, leading to increased autophagy and the upregulation of inflammatory factors. Additionally, Piezo1 enhanced autophagy and IL-6 activation in FLS. In the PGIA model, GsMTx4 inhibited autophagy hyperactivation, significantly reduced the immune-inflammatory response, and exerted a protective effect on spinal bone tissue. Immunofluorescence further confirmed that these effects might be associated with reduced autophagy and inflammatory cytokine expression in macrophages and FLS. These findings highlight the role of Piezo1 in AS pathogenesis, suggesting that Piezo1 may contribute to the immune-inflammatory response in AS through autophagy regulation.


  • Global disease burden attributable to kidney dysfunction, 1990–2019: A health inequality and trend analysis based on the global burden of disease study

    by Yingying Yu, Mingyi Zhang, Yuqin Tang, Chunxia Zhai, Wanqin Hu, Guanghui Yu, Hongyu Sun, Ying Xu, Qiqun Zong, Yuqi Liu, et al.


  • The Global Burden of Disease Attributable to Child and Maternal Malnutrition: 1990–2019

    by Xingyu Gong, Yuqin Tang, Mingyi Zhang, Yingying Yu, Wanqin Hu, Ying Xu, Yuqi Liu, Hongyu Sun, Guanghui Yu, Chunxia Zhai, et al.

    OBJECTIVE: With this study, we aimed to estimate the disease burden attributable to child and maternal malnutrition (CMM) throughout the world between 1990 and 2019. METHODS: The number, age-standardized rate, population attributable fraction of deaths, disability-adjusted life-years, years of life lost, and years lived with disability associated with CMM were estimated using the Global Burden of Disease Study 2019 by age, sex, year, location, and sociodemographic index at the global level. The slope index of inequality and concentration index were employed to measure socioeconomic-related health inequalities across countries. RESULTS: The number (million) of global deaths, disability-adjusted life-years, and years of life lost related to CMM were 2.9, 294.8, and 250.5 in 2019, showing decreases of 60.8, 57.4, and 60.7% since 1990. However, the number of years lived with CMM-related disability increased from 36.0 in 1990 to 44.3 in 2019. Additionally, the age-standardized rates of these 4 indicators showed varying degrees of decline. The global burden of CMM-related conditions differed with age and sex. The burden was the heaviest in western sub-Saharan Africa, especially in Chad. In terms of diseases, neonatal disorders represented the most significant burden attributed to CMM. Additionally, the CMM burden was more concentrated in regions with low sociodemographic indices, shown by the slope index of inequality and concentration index. CONCLUSIONS: The findings of this study highlight the ongoing global burden of CMM, particularly in terms of years lived with disability. Population-wide actions targeting the effective treatment and relief of CMM may reduce the CMM-related disease burden.


  • BNIP3 and DAPK1 methylation in peripheral blood leucocytes are noninvasive biomarkers for gastric cancer

    by Fang Wang, Dingtao Hu, Xiaoqi Lou, Yuhua Wang, Linlin Wang, Tingyu Zhang, Ziye Yan, Nana Meng, Yanfeng Zou


  • Global burden of leukemia attributable to occupational exposure to formaldehyde from 1990 to 2019

    by Ying Xu, Yuqi Liu, Hongyu Sun, Xingyu Gong, Guanghui Yu, Chunxia Zhai, Wanqin Hu, Qiqun Zong, Yingying Yu, Yuqin Tang, et al.

    The objective of this study was to evaluate the worldwide burden of leukemia owing to occupational exposure to formaldehyde (OEF) from 1990 to 2019. Data on leukemia due to OEF were obtained from the Global Burden of Disease Study (GBD) 2019. By region, age, sex, and disease subtype, the numbers and age-standardized rates (ASRs) associated with deaths, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) were analyzed. Annual average percentage change (AAPC) was used to estimate disease burden trends from 1990 to 2019. To measure the risk of leukemia due to OEF, the population attributable fraction (PAF) was introduced. From 1990 to 2019, the number of deaths, DALYs, YLLs, and YLDs for leukemia caused by OEF increased by 44%, 34%, 33%, and 124%, respectively. Regarding the change in ASRs, the age-standardized YLDs (ASYLDs) rate of leukemia due to OEF, which was 38.03% (AAPC = 1.17 [95% confidence interval [CI] 1.11, 1.23]), indicated an increased trend. But the age-standardized mortality rate (ASMR), age-standardized DALY (ASDALY) rate, and age-standardized YLL (ASYLL) rate showed decline trends, with − 11.90% (AAPC = − 0.41 [95% CI − 0.45, − 0.37]), − 14.19% (AAPC = − 0.5 [95% CI − 0.55, − 0.45]), and − 14.97% (AAPC = − 0.53 [95% CI − 0.58, − 0.48]), respectively. In terms of PAFs, there were increasing trends in PAFs of age-standardized deaths, ASDALYs, ASYLLs, and ASYLDs for leukemia caused by OEF, with 20.15% (95% uncertainty interval [UI] 11.76%, 30.25%), 36.28% (95% UI 21.46%, 53.42%), 51.91% (95% UI 35.05%, 72.07%), and 36.34% (95% UI 21.58%, 53.63%), respectively. Across the socio-demographic index (SDI) regions, the leukemia burden caused by OEF was concentrated in middle and high-middle SDI regions. Besides, OEF poses a more serious risk for acute leukemia among the leukemia subtype. Globally, leukemia caused by OEF remains a public health burden. Policies must be developed to avoid the burden of leukemia caused by OEF.


  • Temperature variability associated with respiratory disease hospitalisations, hospital stays and hospital expenses the warm temperate sub-humid monsoon climate

    by Chunxia Zhai, Liangliang Bai, Ying Xu, Yuqi Liu, Hongyu Sun, XingYu Gong, Guanghui Yu, Qiqun Zong, Wanqin Hu, Fang Wang, et al.


  • Health-related quality of life in Chinese SLE patients: evidence from 1568 SLE patients and 2610 healthy controls

    by Yu-Hua Wang, Hong-Yu Sun, Yu-Qi Liu, Xing-Yu Gong, Ying Xu, Qi-Qun Zong, Guang-Hui Yu, Wan-Qin Hu, Chun-Xia Zhai, Lin-Lin Wang, et al.

    Objective To investigate the effects of systemic lupus erythematosus (SLE) on health-related quality of life (HRQOL), the relationship between disease activity and HRQOL, and potential factors affecting HRQOL in Chinese SLE patients. Methods This study recruited 1568 patients and 2610 controls to explore the effects of SLE on HRQOL. The association between disease activity and HRQOL, and the influencing factors of HRQOL were determined in 1568 patients. Then, we prospectively followed 1096 patients to explore the association between reduced disease activity and improved HRQOL, and the influencing factors of improved HRQOL. The Short-Form 36 (SF-36) and SLE disease activity index (SLEDAI) were used to evaluate HRQOL and disease activity. Results Chinese SLE patients had lower HRQOL than controls in all domains (P < 0.001), especially in role-physical (RP) and role-emotional (RE). Compared with SLE patients from outside China, the HRQOL of Chinese patients appeared to be higher in mental component summary (MCS) but lower in RP and RE. SLEDAI was negatively correlated with HRQOL, which was validated using the results of a follow-up study, where SLEDAI reduction was positively associated with HRQOL improvements (P < 0.05). Furthermore, personality, life nervous and experiences of adverse life events may influence HRQOL and HRQOL improvements. Conclusion SLE significantly affected the HRQOL of Chinese patients, especially in RP and RE. Disease activity was negatively correlated with HRQOL. We also found for the first time some factors affecting HRQOL, which can be regarded as the basis for improving the HRQOL of SLE patients.


  • Global disease burden attributed to high sugar-sweetened beverages in 204 countries and territories from 1990 to 2019

    by Hongyu Sun, Yuqi Liu, Ying Xu, Xingyu Gong, Chunxia Zhai, Wanqin Hu, Yuhua Wang, Qiqun Zong, Guanghui Yu, Linlin Wang, et al.